



Abingdon Health plc
("Abingdon Health" or "the Company")

Launch of Salistick™ saliva pregnancy test

*Superdrug to sell Salistick™, the first ever saliva pregnancy test, initially in 400 stores and online
Salistick™ also to launch on [Abingdon Simply Test](#) website*

York, U.K. 19 June 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), announces the launch of Salistick™, the first-ever saliva pregnancy test, in the UK and Ireland.

Salistick™ offers women an improved user experience, with high accuracy for early pregnancy detection, by way of its revolutionary and patented saliva technology which allows for saliva to be used as a sample rather than the traditional urine tests. Salistick™ offers the ability to test anywhere, anytime, and for the testing experience to be shared with a partner and other loved ones.

Abingdon is the exclusive distributor of Salistick™ in the UK and Ireland on behalf of Salignostics Ltd, an Israeli developer of innovative saliva-based diagnostics tests. As well as providing distribution support, Abingdon has been providing Salignostics with contract development services in scaling-up the Salistick™ product for manufacture and will continue to provide Salignostics with contract manufacturing services going forward.

Abingdon is launching Salistick™ with Superdrug, a leading health and beauty retailer in the United Kingdom, initially rolling out into 400 stores and online at [Superdrug.com](#). Superdrug trades from almost 900 stores across the United Kingdom and Ireland.

In addition, Salistick™ will also launch through Abingdon's direct-to-consumer e-commerce channel [Abingdon Simply Test](#). Salistick™ is co-branded Abingdon Simply Test™, with the Abingdon Simply Test™ range now including over 15 self-tests. Abingdon intends to continue expanding the range of innovative self-tests it makes available to consumers through partnering with companies such as Salignostics Ltd to offer the very best in novel self-test technology to the market.

It is estimated that 12.5 million pregnancy tests were performed in the UK in 2022⁽¹⁾. The global pregnancy test kits market was valued at USD 1.70 billion in 2022 and is expected to reach USD 2.28 billion by 2028, growing at a CAGR of 5.08%⁽²⁾.

Chris Yates, CEO of Abingdon Health plc, commented: "We are delighted to announce the launch of Salistick™ initially across 400 Superdrug stores and at Superdrug.com. This novel technology provides women with an enhanced user-experience; offering the ability to test anywhere, anytime, and for the experience to be shared with a partner and other loved ones. We are pleased to have supported our partner Salignostics Ltd through the development process into manufacturing and now commercial launch, and we look forward to deepening our collaboration as we move forward."

Sources:

- (1) <https://www.dailymail.co.uk/sciencetech/article-11039493/Eco-pregnancy-test-99-PAPER-promises-cut-plastic-waste-used-tests.html>
- (2) [Pregnancy Test Kits Market Size, Share, Trends, Growth Forecast \(arizton.com\)](#)

Enquiries

Abingdon Health plc

Chris Yates, Chief Executive Officer
Melanie Ross, Chief Financial Officer
Chris Hand, Non-Executive Chairman

www.abingdonhealth.com/investors/

Via Walbrook PR

Singer Capital Markets (Sole Broker and Nominated Adviser)

Peter Steel, Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)

Tel: +44 (0)20 7496 3000

Walbrook PR Limited

Paul McManus / Phillip Marriage
Alice Woodings

Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

+44 (0)7407 804 654

About Abingdon Health plc

Abingdon Health is a leading lateral flow contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success."

The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes.

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The [Abingdon Simply Test](#) ecommerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland such as pharmacy chains.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

